Research programme: immunotherapeutic vaccines - UbiVac

Drug Profile

Research programme: immunotherapeutic vaccines - UbiVac

Alternative Names: DPV 002; DPV 003; DPV-003HPV; DPV-004

Latest Information Update: 12 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator UbiVac
  • Class Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Human papillomavirus infections

Most Recent Events

  • 12 Sep 2016 Preclinical trials in Human papillomavirus infections in USA (Parenteral) (UbiVac pipeline, September 2016)
  • 12 Sep 2016 UbiVac plans a phase II trial for DPV 002 in Breast cancer (Combination therapy) in USA (UbiVac pipeline, September 2016)
  • 28 Oct 2015 Preclinical trials in Cancer in USA (Parenteral) before October 2015 (UbiVac pipeline, october 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top